MÉRIDIEN-HOTELS-RESORTS
Le Méridien Hotels & Resorts, part of Marriott International, Inc. (NASDAQ:MAR), today marks a milestone: reintroducing the brand to Italy and reimagining an iconic palace to debut Le Méridien Visconti Rome. Following its meticulous renovation and conversion, Le Méridien Visconti Rome, owned and managed by the Toti Group, now boasts custom-designed guestrooms, suites and a transformation of the hotel’s public spaces, including the brand’s signature lobby concept: Le Méridien Hub.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170608005567/en/
“After reintroducing the brand’s flagship hotel in Paris last year, Le Méridien continues to bring glamour to travel with the opening of Le Méridien Visconti Rome, showcasing the best of Italian design and our bold Destination Unlocked positioning,” said George Fleck, Vice President, Global Brand Marketing & Management, Le Méridien Hotels & Resorts. “With its storied past, the hotel sets the stage for guests to discover the destination – whether you are having a coffee in the brand’s signature Hub surrounded by stunning Italian contemporary art or having an aperitif on the hotel’s rooftop with enchanting views of the city.”
Located in the charming Prati district, ideally situated between the Spanish Steps and the Vatican, Le Méridien Visconti Rome is deceivingly residential with 240 guestrooms and suites – ideal for business, leisure and group travel. Led by ara Design International, the hotel’s redesign is rooted in a classic Italian style with understated, geometrical references to Rome’s fabled treasures including the Pantheon.
“Le Méridien brand’s philosophy complements the distinctive traits of Italian culture, art, design and music,” said Marina Toti, CEO, Le Méridien Visconti Rome. “We are proud to be part of Marriott International, and with this magnificent hotel serving as an iconic hotel for Le Méridien, we are confident we will achieve great results and success.”
Mid-Century Modernism Meets Italian Style
The
hotel’s interior design is a contemporary realisation of mid-century
modernism: a material palette of marble, wood and natural textures
juxtapose vibrant textile blocks with references to the work of famous
Italian designer and architect Gio Ponti, who was popular during the
time of the building’s initial construction.
The Hub at Le Méridien Visconti Rome, featuring the Longitude 12 Bar & Bistrot, is a social gathering place for creative people to converse, collaborate and exchange with communal tables and chairs that invite connection and socialising. The focal point of the Hub is the espresso machine, drawing guests to the aroma, sounds and visuals of a master barista at work. The Longitude 12 Bar & Bistrot transforms from a bright and fresh coffee house by day, to a sophisticated cocktail bar by night, revealing a progressive angle on a traditional bar. ara Design International facilitated the design elements of transition from day to night with rotating panels, lowered ambient light and a creative use of mirrors.
The hotel also features a stunning rooftop terrace, offering an inspiring panoramic view of the Eternal City, along with the wide leafy streets of Rome’s fashionable Prati district. The rooftop terrace is the ideal location to enjoy sunset during summertime sipping the brand’s signature Le Méridien Sparkling programme.
Le Méridien Visconti Rome offers ten versatile meeting rooms, totaling 170 square meters. These redesigned meeting rooms reference organic shapes and sophisticated simplicity, ensuring that guests feel continually engaged and inspired.
Unlock Art at Le Méridien Visconti Rome
A
vital element of Le Méridien Visconti Rome is art, providing guests a
different point of view on the classical heritage of Rome, along with a
new way to discover the city and the Italian contemporary art scene.
Guests immediately have a sense of the art programme upon arrival, greeted by a stimulating piece of artwork at the hotel’s entrance: a bas relief map of Rome showcasing the Eternal City’s iconic sites. The hotel’s eclectic art collection features different movements, from abstract art to figurative works, created with different materials, such as the mosaic by Ascanio Renda, the rubber-made artworks by Paolo Canevari, and more traditional oil on canvas paintings. Much of the artwork featured at Le Méridien Visconti Rome is part of the Toti family’s private collection, who chose to feature well-established Italian artists active in the 1980s.
Additionally, Le Méridien Visconti Rome has partnered with La Galleria Nazionale di Arte Moderna in Rome for the brand’s signature Unlock Art™ program, which provides guests with complimentary access to the museum by simply presenting their room key card and the guest pass found in-room. Founded in 1883, the museum is dedicated to modern and contemporary art and features one of the greatest collections in Italy with more than three thousand works, including paintings, sculptures, drawings, and engravings.
Rooms at Le Méridien Visconti Rome start from €200 per room per night. For more information, please visit: www.lemeridien.com/rome .
###
About Le Méridien
With more
than 100 Hotels & Resorts worldwide and the strongest, most globally
diverse portfolio in its history, the Paris-born Le Méridien brand
connects the curious and creative-minded traveler to unexpected and
engaging experiences within their destination. With its brand promise of
“Destination Unlocked”, Le Méridien has transformed numerous guest touch
points through global partnerships with creative minds. Plans call for
dynamic portfolio
expansion
within the next five years in some of the world’s most
exciting destinations. For more information, please visit LeMéridien.com
or follow us on social media – Facebook
,
Instagram
,
and Twitter
.
About Marriott International, Inc.
Marriott
International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA,
and encompasses a portfolio of more than 6,100 properties in 30 leading
hotel brands spanning 122 countries and territories. Marriott operates
and franchises hotels and licenses vacation ownership resorts all around
the world. The company also operates award-winning loyalty programs:
Marriott Rewards®, which includes The Ritz-Carlton Rewards®, and
Starwood Preferred Guest®. For more information, please visit our
website at www.marriott.com
,
and for the latest company news, visit www.marriottnewscenter.com
.
In addition, connect with us on Facebook
and @MarriottIntl on Twitter
and Instagram
.
About Toti Group
The main
activities of Toti Group are carried out through the Silvano Toti
S.p.A., a Financial Holding owned by the Toti family. The Group, with
its long-lasting tradition and international acclaim, was founded by
Antonio Lamaro in the Twenties. Thanks to Silvano Toti, the company
continued to expand, establishing a strong and increasing presence
throughout the country and abroad. Toti Group is in continuous
advancement and evolution, taking advantage of the changes over time,
introducing new technology and maintaining a high competitive edge over
Italian and foreign markets. Today the Toti Group with its extraordinary
know-how and history, is a leader in the construction, financial,
administrative, technical, commercial and management sectors, thus
allowing the Group’s success. In addition to the soon-to-be-unveiled Le
Méridien Visconti Rome, Toti Group has recently opened Palazzo
Scanderbeg, located near Trevi Fountain and make continuous improvements
to Hotel Capo d’Africa by the Colosseum. For more on Toti Group: www.silvanototi.it
ara Design International
ara
Design was established in 1996 by Andre Avedian and Harry Gregory,
specialising in the global hospitality sector. The company has since
secured a reputation of being at the forefront of innovative and
inspiring design, focusing on quality and integrity for top brand
operators all over the world. From regional offices in Europe, Middle
East and Far East, the company has completed interior design projects in
more than 30 countries, including 5-star hotels, resort spas, boutique
hotels, restaurants and private residences. For more on ara Design
International: www.aradesign.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608005567/en/
Contact:
Media Contacts
Sara Migliore
Director
of Communications Italy
sara.migliore@starwoodhotels.com
or
Katie
Roberts
Global Communications, Le Méridien Hotels & Resorts
Katie.roberts@starwoodhotels.com
or
Day
One Agency
US PR Agency, Le Méridien Hotels & Resorts
LeMeridien@D1A.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom